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Abstract Cardiac allograft vasculopathy (CAV) is one of the
main causes of late-stage heart failure after heart transplanta-
tion. CAV is characterized by concentric luminal narrowing of
the coronary arteries, but the exact pathogenesis of CAV is still
not unraveled. Many researchers show evidence of an alloge-
neic immune response of the recipient, whereas others show
contrasting results in which donor-derived cells induce an im-
mune response against the graft. In addition, fibrosis of the
neo-intima can be induced by recipient-derived circulating
cells or donor-derived cells. In this review, both donor and
recipient sides of the story are described to obtain better insight
in the pathogenesis of CAV. Dual outcomes were found regard-
ing the contribution of donor and recipient cells in the initiation
of the immune response and the development of fibrosis during
CAV. Future research could focus more on the potential syner-
gistic interaction of donor and recipient cells leading to CAV.
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αSMA Alpha smooth muscle actin
ACE Angiotensin-converting enzyme
APC Antigen-presenting cell




ECPC Extra cardiac progenitor cells
EMT Epithelial-to-mesenchymal transition
Endo-MT Endothelial-to-mesenchymal transition
EPC Endothelial progenitor cells
H-CAV Histopathological CAV
HLA Human leukocyte antigen
IFN-γ Interferon-γ
IL Interleukin
MHC Major histocompatibility complex
MICA MHC class 1 chain-related A
PD-L1 Programmed death-ligand1
SMC Smooth muscle cell
TGF- β Transforming growth factor-β
Introduction
Cardiac transplantation is often successfully applied in the
treatment of end-stage heart failure [1]. Since 1982, more than
110,000 heart transplantations have been performed globally
and these numbers are still rising [2]. Over the years, early
survival rates of recipients, which received a heart transplan-
tation, have significantly improved [2]. In the first months
after transplantation, acute rejection of the transplanted heart
can occur [3].Much progress has beenmade in controlling this
acute rejection phase, resulting in increased early survival rates
[2]. However, chronic rejection is one of the major issues that
affects long-term survival of heart transplant recipients [4].
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One of the main causes of chronic rejection is cardiac allo-
graft vasculopathy (CAV) [1–5]. CAV is an accelerated form
of coronary artery disease [6] and affects both males and fe-
males [3]. The mechanism by which CAV develops is not
fully elucidated, but it is estimated that 50 % of heart trans-
plantation recipients are developing CAV within 5 years after
transplantation [7]. Hence, CAV is responsible for 10–15% of
cardiac deaths after transplantation [8]. CAV affects the vas-
culature of the transplanted heart, resulting in congestive heart
failure, arrhythmias, myocardial infarction, or sudden cardiac
death [1, 9]. Both immunologic factors and non-immunologic
factors, such as age, gender, and brain injury, are involved in
the development of CAV, although immunologic factors have
shown to be the most important players [5, 10].
CAV is characterized by diffuse intimal thickening leading
to progressive narrowing of the coronary arteries [5, 11].
There are different types of lesions in CAV patients, including
intimal hyperplasia, atherosclerotic lesions, and vasculitis [3].
Within the lesions of intimal hyperplasia, three histopatholog-
ical phenotypes of CAV can be observed: 1) loose connective
tissue with inflammatory cells, 2) lesions with smooth muscle
cells, and 3) fibrotic lesions (Fig. 1) [12]. Most commonly
seen characteristic in CAV is fibromuscular hyperplasia of
the intima, which also distinguishes CAV from atherosclerosis
[8]. Ultimately, progressive narrowing of the coronary artery
results in critical stenosis and ischemia of the graft [3].
The exact mechanism in which CAV is induced after heart
transplantation is not elucidated, but it is known that both
donor and recipient cells are involved [13]. The question re-
mains whether cells of the recipient react on cells of the donor
heart or vice versa. Multiple researchers have studied the
mechanism of CAV, and the results were often contradictory.
For example, one study revealed that donor dendritic cells
(DCs) transmigrate through host secondary lymphoid organs,
thereby promoting T-lymphocytes of the recipient, which may
promote graft rejection [14]. However, others propose that
allo-recognition of donor major histocompatibility complexes
(MHC) by recipient immune cells leads to graft rejection
[15]. The same is true for the development of fibrosis; are
recipient-derived endothelial progenitor cells or endothelial-
mesenchymal transition of donor cells responsible for the pro-
gressive lesion formation [16, 17]? The immune response
could be the initial trigger for fibrosis; however, other mech-
anisms of fibrosis may be involved as well. In this overview,
recipient and donor sides of the stories (immune response and
fibrosis) are highlighted to obtain better insights in the patho-
genesis of CAV.
Cardiac Allograft Vasculopathy: Immune Response
Recipient-Derived Immune Response
According to multiple research groups, the onset of CAV is
caused by an immune response of the recipient against the
donor [3, 5, 9, 18]. The hypothesis is that after the heart is
Fig. 1 Microscopic pictures of the three histopathological phenotypes of
CAV in the coronary artery of heart transplantation recipients. aH-CAV 1
lesion, which shows infiltration of lymphocytes in the neo-intima layer;
H-CAV 2 lesion, showing infiltration of lymphocytes together with infil-
tration of smoothmuscle cells and formation of connective tissue; H-CAV
3 lesion, which shows a large fibrotic intimal lesion without inflammatory
infiltrate (αSMA staining, magnification ×100, line indicates 100 μm). b
Microscopic pictures of occluded coronary arteries by a thrombus or
fibrotic tissue, respectively (HE staining, magnification ×20, line indi-
cates 1 mm)
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transplanted, both cellular and humoral immune responses of
the recipient are generated against the graft [3]. The immune
response of the recipient can be triggered via a (1) direct, (2)
an indirect, or a (3) semi-direct pathway (Fig. 2) [18–21].
Although all three pathways can be involved, the semi-direct
and direct pathways are less well described in the process of
CAV.
(1) In the direct pathway, recipient T-lymphocytes are acti-
vated after recognition of allogeneic MHCs (with a foreign
antigen) of donor antigen presenting cells (APCs) [18].
(2) The indirect pathway is activated by allo-recognition of
processed foreign antigens by APCs of the recipient itself
[19]. The recognition of donor antigens on recipient APCs
leads to the activation and proliferation of T-lymphocytes.
(3) The semi-direct pathway, a new pathway which may be
involved, is activated by recipient APCs, presenting donor
MHC molecules on their surface [20]. The theory is that re-
cipient APCs acquire donor MHC via cell-cell interaction (in-
tercellular exchange) with donor cells or via the uptake of
donor-derived exosomes [21]. The subsequent presentation
of donor antigens by donor MHC molecules on recipient
APCs will mount a host T-lymphocyte response, leading to
the development of chronic rejection.
In all three pathways, the activation of T-lymphocytes will
lead to secretion of cytokines such as interleukin-2 (IL-2) and
interferon-γ (IFN-γ) [22]. Cytotoxic T-lymphocytes, B-lym-
phocytes, and macrophages are activated by these cytokines.
In addition, endothelial cells are activated and start expressing
vascular cell adhesion molecules, which leads to the recruit-
ment of more immune cells [7]. The pro-inflammatory cyto-
kines also enhance the proliferation of smooth muscle cells
(SMCs) [15]. Activated B-lymphocytes begin to secrete
donor-specific HLA antibodies. These antibodies are impor-
tant mediators in the development of CAV [23, 24]. They are
able to bind the allo-antigens to enable complement factor
binding, leading to the activation of the complement system.
Furthermore, immune cells, such as macrophages, can bind
the donor specific antibodies, which activate antibody-
mediated lysis [18]. All of the indicated pathways will ulti-
mately result in vascular injury, ischemia, and damage to the
allograft [9].
In addition, there is also evidence that Bautoimmunity^
plays an important role in the development of CAV [25].
For example, in lung transplant recipients, chronic allograft
rejection developed even in the absence of human leukocyte
antigen (HLA) antibodies [26]. An explanation for this phe-
nomenon might be the presence of antibodies against non-
HLA antigens [25], but the question remains which non-
HLA antigens are involved. Recent studies showed that
Bauto-antibodies^ against cardiac myosin and vimentin can
be detected after heart transplantation [27, 28]. These Bauto-
antibodies^ are probably induced via antigen mimicry be-
tween the donor MHC peptides and auto-antigen peptides of
the recipient [28]. T-lymphocytes, which are activated by an
indirect allo-immune response, are able to induce chronic re-
jection by recognition of these auto-antigens [29]. It has been
shown in mouse models that induction of tolerance to cardiac
myosin leads to a decrease in chronic rejection and an increase
in long-term survival after heart transplantation [30]. There-
fore, reactivity of the T-lymphocytes toward auto-antigens is
likely involved in the development of CAV [28].
Furthermore, the development of anti MHC-class-1-chain-
related-A (MICA) antibodies may play a role in the develop-
ment of CAV [23, 25]. Normally, these antigens are expressed
in fibroblasts, monocytes, and endothelial cells [24]. In CAV,
there is an increase in MICA expression on endothelial cells
[31]. In addition, allo-antibodies against MICA are detected,
which actively induce an immune response and cause damage
to the endothelium [23].
Cytomegalovirus (CMV) infection has also been known to
affect transplantation outcome and CAV. Systemic replication
of CMV is associated with increased risk of rejection of the
graft and the development of CAV [32]. The theory is that
CMV infection induces inflammatory responses of the recip-
ient, thereby contributing to vascular damage and accelerating
the pathogenesis of CAV [33].
The trigger of these responses (direct, indirect, and
semi-direct pathways, Bautoimmunity^ and CMV infec-
tion) ultimately leads to the proliferation of smooth mus-
cle cells (SMCs), accumulation of extracellular matrix and
hyperplasia of the intima of the vessel wall (Fig. 2) [15,
22, 23].
Donor-Derived Immune Response
Next to the recipient-derived immune response, there is also
evidence that donor factors are involved in the immune-
pathogenesis of chronic rejection and CAV [34, 35]. Donor
factors contributing to CAV include the status of the donor
heart and donor-derived cells transplanted during the proce-
dure. The brain death status of the donor greatly influences
CAV development [36, 37]. The release of catecholamines
during brain death induces endothelial injury leading to cyto-
kine release and MHC up-regulation on donor endothelium
[38]. This pathway is mainly investigated in kidney transplant
models [37, 39]. However, endothelial dysfunction is gener-
ally accepted as one of the strongest predictors of CAV [40].
This process in the donor heart accelerates the early allo-
immune response leading to CAV initiation.
Donor-derived cells also play an important role in the path-
ogenesis of CAV. The current theory is that remaining donor
cells within the transplanted heart are able to actively induce
an immune response of recipient immune cells [41, 42]. It has
been shown that donor-derived immune cells are able to mi-
grate to lymph nodes of the recipient and locally present allo-
antigens [43]. Heart-derived donor dendritic cells (DCs) can
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already be found three hours after transplantation in secondary
lymphoid organs and are not as short-lived in recipients as
previously thought [41]. A rodent animal study demonstrated
that donor DCs can be found in T-lymphocyte areas of the host
spleen and hepatic lymphnodes [35]. Hereby, cluster forma-
tion of donor DCs and host T-lymphocytes was initiated that
activated T-lymphocyte proliferation [35]. These results sug-
gest a donor-derived immune response, initiated by donor
DCs.
In addition to donor DCs, the functional activity of donor
CD4 T-lymphocytes was studied. In a mouse model, the de-
velopment of autoimmune reactions after heart transplantation
and the contribution to CAV was analyzed [42]. Donor CD4
T-lymphocyte allo-recognition of MHC-II on recipient B-
lymphocytes enhanced the production of auto-antibodies,
thereby contributing to the development of CAV [42]. When
donor CD4 T-lymphocytes were depleted, a significant de-
crease in both antibody and complement deposition was ob-
served in the allograft [42]. Furthermore, transplant studies
showed a mixture (chimerism) of donor and recipient
leucocytes, including T-lymphocytes, in heart transplant recip-
ients [44]. However, to what extent donor T-lymphocytes are
contributing to CAV after heart transplantation is still
unknown.
The expression of donor programmed death-ligand 1 (PD-
L1) is also involved in the development of CAV [45]. This
ligand plays an important role in the regulation of an allo-
immune response by regulating activation of CD4 and CD8
T-lymphocytes [46]. Donor deficiency of PD-L1 accelerates
allograft rejection and the development of CAV compared to
PD-L1 deficient recipients [45]. Deficiency of donor PD-L1
leads to the secretion of IFN-γ and proliferation of allo-
reactive T-lymphocytes of the recipient, thereby promoting a
recipient allo-immune response [46]. These findings show that
PD-L1 expression on cardiac tissue or leukocytes of the donor
is critical in the regulation of an allograft immune response in
heart transplant recipients [45, 46].
In addition, it has been shown that donor-derived selectins
play an important role in the development of CAV [34].
Selectins are involved in adhesion of leukocytes to the endo-
thelium of the vessel wall [34]. Donor-derived E and P-
selectin, located on the endothelium of the graft, interact with
L-selectin on recipient-derived leukocytes, thereby enhancing
the attraction of immune cells [34]. In rats, there is a signifi-
cant correlation between the amount of P-selectin expression
and intimal thickening of the vessel wall [47]. Corresponding
results were found in human recipients with a lung allograft
[48]. Furthermore, an increased long-term graft survival with
Fig. 2 Pathways in recipient-derived immune response. Primary event is
the recognition of allo-antigens by T-lymphocytes via one of the indicated
pathways. The direct pathway is activated by the recognition of MHC
complexes with a foreign HLA-antigen (red) presented by donor APCs
(red). The indirect pathway is activated when T-lymphocytes recognize
processed allo-antigens presented by recipient APCs (green). The semi-
direct pathway is activated when T-lymphocytes recognize allo-antigens
presented on donor MHC on recipient APCs. In addition, non-HLA an-
tigens might be involved, which are bound by Bauto-antibodies^. This
will lead to complement activation and T-lymphocyte activation. Activa-
tion of B-cells can be initiated by donor DCs and donor T-lymphocytes.
All of the indicated pathways lead to activation of T-lymphocytes, which
start to secrete pro-inflammatory cytokines such as IFN-γ. The secretion
of IFN-γ recruits more immune cells, such as NK-cells andmacrophages,
and acts on SMCs. The proliferation of SMCs will ultimately result in
proliferation of the intima and occlusion of the artery, which are the
characteristics of CAV
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minimal vasculopathy was seen in recipients lacking donor-
expressed selectins. This indicates the importance of donor-
derived selectins in the development of CAV [49].
According to this accumulating evidence, there is a donor-
derived immune response causing the development of allo-
graft vasculopathy and donor cells are involved in regulating
the allo-immune response of the recipient. Since this is a rel-
atively new insight, more focus on these aspects is needed to
reveal the exact mechanism and to define all of the donor and
recipient cells involved.
Differences in Immune Response in Gender Mismatch
Transplantations
Interesting differences in transplantation outcome have been
reported between males receiving a female heart or females
receiving a male heart, the so called donor-recipient gender
mismatch transplantations [50]. Donor-recipient gender mis-
match has been shown to influence the early pathogenesis of
CAV [51]. At the vascular level, male recipients with a female
allograft developed significantly higher amounts of intimal
thickening within one year of transplantation [52]. Females
receiving a male allograft only developed non-severe thicken-
ing of the intima [52]. The combination of male recipients
receiving a female heart has been correlated with worse out-
comes at several levels besides CAV [53]. Which factors are
involved is still under investigation, but there is evidence that
smaller heart size, shear stress, and loss of the estrogen-
protected environment of the female heart are important fac-
tors [1, 52]. Additionally, these factors contribute to initial
endothelial damage of the coronary arteries, thereby initiating
CAV development. Furthermore, the vasculature of the female
heart is thought to be immunologically more susceptible com-
pared to male hearts [52]: a possible explanation is that the
vasculature of the female heart expresses more HLA and non-
HLA endothelial antigens than their male counterparts [54],
which leads to triggering of the male immune system and
thereby an earlier development of CAV [52].
At the organ level, contrasting studies showed higher inci-
dents of rejection of female recipients receiving a male heart
[55]. These high rejection rates might be explained by greater
immuno-competence of the female by developing HLA anti-
bodies against H-Y antigens, presented by cells of the male
heart [55]. Presentation of these antigens can lead to an im-
mune response followed by the formation of allogeneic anti-
bodies [25]. The allogeneic immune response against H-Y
antigens can lead to graft destruction and ultimately results
in rejection of the male heart [56].
Based on these findings, donor-recipient gender mismatch
in heart transplantation is followed by dual outcomes. Trans-
plantation of male hearts into females is characterized by
higher rejection rates, but in the end, a higher long-term sur-
vival [55]. Transplantation of female hearts into males is
characterized by an earlier development of CAV [55]. How-
ever, some of the studies were limited by the small numbers of
gender mismatch transplantations available [51].
Cardiac Allograft Vasculopathy: Fibrosis
The before-mentioned immune reactions could be followed
by fibrosis, which plays an important role in the progressive
thickening of the neo-intima and subsequently in the develop-
ment of CAV [57]. In some recipients, the neo-intima of the
coronary arteries almost completely exists of fibrotic tissue
[58]. It is known that some inflammatory cells of the recipient,
such as T-lymphocytes and macrophages, are involved in the
initiation of the fibrotic process [57]. The secretion of cyto-
kines like IFN-γ and transforming growth factor-β (TGF-β)
by T-lymphocytes leads to the activation of macrophages and
fibroblasts respectively [25, 59]. It has been shown that espe-
cially recipient-derived macrophages type 2 (M2) are in-
creased in the neo-intima of CAV arteries [60, 61]. These
macrophages are involved in tissue remodeling and matrix
deposition and play an important role in the development of
fibrotic lesions [60, 62]. They are known to infiltrate the allo-
graft and produce growth factors, such as TGF-β, which in-
creases neo-intimal proliferation [61]. However, more cell
types are involved. Next to identified circulating cells of the
recipient, there is also evidence of the involvement of donor-
derived cells [13, 63].
Recipient-Derived Circulating Cells
There is evidence emerging for the role of recipient
endothelial progenitor cells (EPCs) in CAV [29]. EPCs
(CD133+CD34+Flk1 [VEGF-R1]+ in bone marrow, CD31
[PECAM-1]+CD146+vWF+NOS+ in circulation), are bone
marrow-derived cells, which have endothelial regenerative
properties [64]. Healthy endothelium of the vessel wall nor-
mally undergoes degeneration and regeneration [65]. By an
imbalance in these processes, endothelial dysfunction occurs
that can lead to injury of the vessel wall [65]. EPCs are able to
adhere to the sides of injury and promote healing and repair
[66]. Increased numbers of circulating EPCs have been shown
to prevent cardiovascular diseases and to reduce neo-intimal
hyperplasia in men [67]. However, upon heart transplantation,
the protective role of EPCs changes and EPCs of the recipient
may participate in the pathogenesis of CAV (Fig. 3a) [16, 65,
68]. Circulating EPCs attach to the vessel wall and start to
proliferate as a result of a persistent allograft immune response
[68]. The EPCs become uncontrolled, thereby contributing to
chronic allograft rejection via accumulation of endothelial
cells and SMCs, which in turn leads to occlusive narrowing
of the coronary vessels [65]. Upon culturing mononuclear
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cells from blood, fewer colonies of circulating EPCs were
found in heart transplantation recipients with vasculopathy
during chronic rejection, compared to transplantation recipi-
ents without evidence of vasculopathy [16]. Interestingly,
there was also an increase of attached recipient EPCs in the
coronary arties of the donor heart, where eventually CAV
developed [16]. The hypothesis is that excessive numbers of
recipient EPCs differentiate into endothelial cells and SMCs,
and that an overload of these cells leads to hyperplasia of the
neo-intima and fibrosis [16, 68]. The number of circulating
EPCs becomes depleted and thereby the protective effects, as
mentioned before, are lost [16].
In addition to EPCs, there is also evidence for a role of
recipient-derived extra-cardiac progenitor cells [69]. These
extra-cardiac progenitor cells are thought to be derived from
mesenchymal precursor cells and migrate toward the allograft
where they differentiate into multiple cell lineages [70]. En-
graftment of recipient-derived cells in the allograft, such as
cardiac progenitor cells, resulted in chimerism of the
transplanted heart, which can be beneficial by repopulating
the niches of rejected donor cells of the graft [66, 71, 72]
However, chimerism of the transplanted heart by extra-
cardiac progenitor cells has been shown to be linked to CAV
and intimal fibrosis [70]. A possible explanation is that, during
cell death of donor cells, an immune response is locally trig-
gered leading to vascular damage of the coronary arteries [64].
In response to tissue injury, recipient-derived mesenchymal
precursor cells are attracted and migrate toward the allograft
where they differentiate into fibroblasts [73]. In rats suffering
from chronic allograft rejection, it has been shown that more
than 65 % of fibroblasts in the allograft are of recipient origin
[73]. When these fibroblast are activated upon inflammation,
they start to proliferate and produce extracellular matrix
(ECM) [74]. Ongoing inflammation in chronic rejection leads
to a continuous fibrogenic environment, which ultimately
leads to fibrosis of the neo-intima in CAV [57, 71, 73, 74].
Although chimerism of the transplanted heart provides ev-
idence for the involvement of recipient-derived circulating
cells, the contribution of these cells in the pathogenesis of
fibrosis in human CAV is still conflicting and remains to be
resolved.
Donor-Derived Cells
Besides the contribution of recipient-derived cells, there is
also evidence that donor cells are involved in the formation
of fibrosis [13, 64] It is thought that especially donor-derived
SMCs produce extracellular matrix and contribute to the for-
mation of fibrotic lesions in the neo-intima [65]. In CAV, most
of the cells in the neo-intima of coronary vessels express
markers of SMCs [75]. In human CAV, the majority of these
cells are derived from the graft and not from the host [13]. It is
not known where these SMCs are originating from. It is pos-
sible that resident intimal SMCs expand in number upon in-
flammation or that they derive from the media and migrate
toward the intima to sites with vascular damage (Fig. 3b) [9].
There is also evidence that these donor-derived SMCs origi-
nate from endothelial mesenchymal transitions of donor cells
[17]. However, the exact role of these donor-derived SMCs
needs to be clarified.
Endothelial-to-mesenchymal transition (Endo-MT) and
epithelial-to-mesenchymal transition (EMT) have shown to
Fig. 3 Role of recipient and
donor-derived cells in concentric
narrowing and fibrosis of the cor-
onary artery. a Recipient-derived
circulating cells, such as EPCs
and ECPCs, contribute to con-
centric narrowing and fibrosis of
the coronary arteries. Increased
accumulation of circulating cells
bound to the vessel wall induces
differentiation of these cells to-
ward fibroblasts, SMCs, and en-
dothelial cells, which enhances
concentric narrowing of the coro-
nary arteries. b. Donor-derived
cells, such as SMCs, are migrat-
ing from atherosclerotic lesions or
the media layer toward the neo-
intima. Accumulation of donor-
derived SMCs and production of
ECMwill lead to the expansion of
the neo-intima resulting in
narrowing and fibrosis of the cor-
onary artery
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be potential contributors to neo-intima formation [76–78].
Endo-MT is the trans-differentiation of endothelial cells into
mesenchymal cells, such as SMCs and fibroblasts, whereas
EMT represents the trans-differentiation of epithelial cells into
mesenchymal cells [17, 76]. This process normally occurs
during certain stages of embryonic development of the heart
under influence of TGF-β signaling and is implicated in fibro-
sis formation [76, 79]. For example, biopsies of human kidney
transplants with allograft vasculopathy showed a loss of epi-
thelial markers and an increase in mesenchymal markers [80].
The same trend was observed in studies with cardiac fibrosis,
where endo-MT significantly contributed to the development
of fibrosis in chronic cardiac disease [81]. It is thought that
both endothelial and epicardial-derived cells of the donor, lo-
cated on the transplanted heart, use this mechanism to differ-
entiate into SMCs and myofibroblasts, thereby contributing to
the development of neo-intima fibrosis in CAV [76, 81–83].
Although this hypothesis is gaining attention, it still needs to
be unraveled where these donor-derived cells come from.
Donor-Derived Atherosclerotic Plaques
Next to individual donor-derived cells, it has been suggested
that atherosclerotic plaques in coronary vessels of the donor,
pre-existing in the transplanted heart, influence the outcome of
CAV in the recipient [84]. The atherosclerotic lesions make
the intima and the endothelium of the donor coronary arteries
more vulnerable for the development of fibrotic lesions during
CAV [12]. In these arteries, the fibrotic process and prolifera-
tion of immune cells and SMCs was already ongoing in the
plaque and could further develop in the transplanted heart,
thereby causing neo-intima formation (Fig. 3b). It is also pos-
sible that these atherosclerotic lesions develop after transplan-
tation, but there seems to be a correlation between pre-existing
atherosclerotic lesions and a more fibrotic CAVoutcome [8].
In conclusion, it appears that not only inflammatory cells of
the donor are involved in the pathogenesis of CAV, but also
donor-derived cells, such as endothelial cells, epicardial cells,
and smooth muscle cells. In addition, presence of atheroscle-
rotic plaques might be correlated to fibrotic lesions in CAV.
These findings provide new insights in a possible role for the
donor in the development of neo-intima fibrosis in CAV; how-
ever, this is still under debate.
Interventions
Activation of the immune system of the recipient, for example
by contact of donor- and recipient cells, should be avoided.
Ideally, when transplanting a solid organ, there is no transfer
of donor immune cells to trigger an immune response. In the
future, this might be achieved by, for instance, ex vivo
perfusion of the donor organ, clearing all immune cells from
the graft [85]. When ex vivo heart perfusion would be appli-
cable in future clinical practice, therapies necessary for that
specific donor organ could be applied to prolong graft survival
as experimentally tested in lung transplantation [86, 87]. The-
se therapies could target pathways involved in endothelial
damage, cell death, ischemia reperfusion-injury, and many
other processes related to CAV. For each donor organ,
Bpersonalized medicine^ could be applied with the specific
factor to restore the damaged organ and get better long-term
outcomes after transplantation.
Multiple prophylactic approaches have been used to pre-
vent the development of CAV [88]. Modification of risk strat-
egies may slow the progression of CAV, including the preven-
tion of CMV infection and endothelial damage caused by the
immune response in general [89]. Environmental infection of
CMVafter transplantation can activate immune cells of donor
and recipient [33]. However, most likely, this would not have
an effect on the long-term fibrotic response.
Currently used therapeutic interventions, such as statins,
angiotensin-converting enzyme (ACE) inhibitors and immu-
nosuppressive medications are not always successful in the
treatment of CAV [88]. These therapies are not specifically
developed for CAV, but are developed for cardiovascular dis-
eases in general. Statins for example, did show anti-
inflammatory properties by significantly reducing acute cellu-
lar rejection episodes, however, were never proven to prevent
Table 1 Summary based on recent findings of interacting cells derived
from both donor and recipient in the pathogenesis of CAV
Cardiac allograft vasculopathy: immune response
Recipient-derived immune response Donor-derived immune response
Alloimmune response
[1] Direct pathway Donor DCs
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Female recipients: earlier development CAV
Cardiac allograft vasculopathy: fibrosis
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CAV [90, 91]. Therefore, it is most likely that they do not
specifically inhibit the immune- and fibrotic processes in
CAV. The most advanced therapy is the use of proliferation
inhibitors, a new class of immunosuppressants, such as evero-
limus and sirolimus [92]. These are able to reduce intimal
thickening in CAV by inhibiting cell proliferation [93]. In
CAV, proliferation of immune cells and SMCs is described,
which would suggest that these proliferation inhibitors are
effective as long proliferation of these cells would occur.
Therefore, timing of these therapies is very important, since
early after transplantation, they disrupt fibroblast function and
therefore wound healing and late after transplantation, they
don’t show any effects [94, 95]. These proliferation inhibitors
showed promising results in preliminary studies, however,
remain not implicated in most clinical centers [96].
Conclusions
CAV is the leading cause of death after heart transplan-
tation, although the pathogenesis is not fully resolved
[1]. Until recently, CAV has been considered to be in-
duced by either a recipient-derived immune response or
a donor-derived immune response [5]. However, more
evidence points to the possibility of a dual action of
donor and recipient. By comparing both sides of the
story, more knowledge about the pathogenesis of CAV
can be obtained (see Table 1 for summary of presented
findings).
In conclusion, CAV is a complex disease with an unre-
vealed pathogenesis. Presumably, CAV is not induced only
by the donor or recipient. Based on current research, it is clear
that both donor and recipient cells are involved [9, 42, 43]. It
appears the immune system of the recipient is the most impor-
tant player in the development of CAV, since immune activa-
tion of the recipient initiates allograft immune responses,
which ultimately leads to vascular damage [10]. Even without
the interference of donor-derived immune cells, CAV can
probably develop. Donor immune cells, derived from the
transplanted heart, are able to enhance the immune response
of the recipient, but it seems that they are not able to induce
CAV independently. Most likely, there is some kind of syner-
gic interaction between recipient and donor cells, which ac-
celerates the pathogenesis of CAV. More research is needed to
completely identify the dual interaction of both donor and
recipient cells. Some studies were using only animal experi-
ments or experimental CAV; therefore, it would be interesting
to investigate whether the outcomes of animal studies are con-
sistent in human CAV samples. The outcomes based on pre-
vious experimental models should in the future be extrapolat-
ed to the human transplant recipient to elucidate the potential
enhancing role of donor cells in the pathogenesis of CAV.
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